In clinical trials, medical coding standardizes raw research data — such as adverse events, medical histories, and concomitant medications — using global regulatory dictionaries like MedDRA and WHODrug rather than healthcare billing codes.
Clinical trial coding vs healthcare reimbursement coding
Medical coding in clinical research serves a completely different objective from healthcare billing. While hospital and provider coding (ICD-10-CM, CPT, HCPCS Level II) focuses on insurance claims, fee schedules, and reimbursement, clinical trial coding focuses on patient safety, trial protocol standardization, and regulatory compliance.
During a clinical trial, investigator sites worldwide record patient observations in unstructured text. Medical coding transforms these free-text entries into standardized, universally understood alphanumeric codes stored in Electronic Data Capture (EDC) systems.
MedDRA: Coding adverse events and medical conditions
The Medical Dictionary for Regulatory Activities (MedDRA), maintained by the International Council for Harmonisation (ICH), is the global standard for coding adverse events (AEs), symptoms, and diagnoses in clinical trials.
MedDRA operates across a 5-tier hierarchy: System Organ Class (SOC) at the broadest anatomical level, down through High-Level Group Terms (HLGT), High-Level Terms (HLT), Preferred Terms (PT), and Lowest Level Terms (LLT). This multi-level structure allows biostatisticians and safety monitors to detect adverse safety signals at both granular and systemic levels.
WHODrug: Standardizing concomitant medications
The WHODrug Dictionary, maintained by the Uppsala Monitoring Centre (UMC), standardizes all prior and concomitant medications taken by clinical trial participants.
WHODrug maps trade names, active chemical ingredients, and Anatomical Therapeutic Chemical (ATC) classifications. This allows clinical data managers to assess potential drug-drug interactions and monitor compliance with protocol exclusion criteria.
From investigational candidate to commercial NDC and J-Code
Throughout Phase 1, Phase 2, and Phase 3 clinical studies, an investigational product operates under an FDA Investigational New Drug (IND) application, identified by protocol research codes.
Once a candidate proves safety and efficacy in Phase 3 trials and receives FDA approval (via NDA or BLA), it enters the commercial healthcare system. The labeler lists the product with the FDA and assigns its National Drug Code (NDC). If the drug is clinician-administered, it may later receive a drug-specific HCPCS Level II code from CMS; until then, claims may use an unclassified code. Administration services are reported with existing CPT codes.
Questions
Why aren't NDCs or J-codes used during clinical trials?
Investigational drugs in clinical trials are unapproved candidates without commercial packaging or retail distribution. They do not yet bill on insurance claims, so trial data managers use MedDRA and WHODrug to record safety data rather than billing identifiers.
What are the five levels of the MedDRA hierarchy?
MedDRA consists of: 1. System Organ Class (SOC), 2. High-Level Group Term (HLGT), 3. High-Level Term (HLT), 4. Preferred Term (PT), and 5. Lowest Level Term (LLT).
How do EDC systems perform automated medical coding?
Modern Electronic Data Capture (EDC) platforms use automated coding algorithms that compare investigator entries against MedDRA and WHODrug synonym lists, routing unmatched entries to human medical coders for manual review.